Literature DB >> 25154026

Reaction coupling between wild-type and disease-associated mutant EZH2.

Brooke M Swalm1, Sarah K Knutson, Natalie M Warholic, Lei Jin, Kevin W Kuntz, Heike Keilhack, Jesse J Smith, Roy M Pollock, Mikel P Moyer, Margaret Porter Scott, Robert A Copeland, Tim J Wigle.   

Abstract

EZH2 and EZH1 are protein methyltransferases (PMTs) responsible for histone H3, lysine 27 (H3K27) methylation. Trimethylation of H3K27 (H3K27me3) is a hallmark of many cancers, including non-Hodgkin lymphoma (NHL). Heterozygous EZH2 point mutations at Tyr641, Ala677, and Ala687 have been observed in NHL. The Tyr641 mutations enhance activity on H3K27me2 but have weak or no activity on unmethylated H3K27, whereas the Ala677 and Ala687 mutations use substrates of all methylation states effectively. It has been proposed that enzymatic coupling of the wild-type and mutant enzymes leads to the oncogenic H3K27me3 mark in mutant-bearing NHL. We show that coupling with the wild-type enzyme is needed to achieve H3K27me3 for several mutants, but that others are capable of achieving H3K27me3 on their own. All forms of PRC2 (wild-type and mutants) display kinetic signatures that are consistent with a distributive mechanism of catalysis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25154026     DOI: 10.1021/cb500548b

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  10 in total

Review 1.  Polycomb genes, miRNA, and their deregulation in B-cell malignancies.

Authors:  Gang Greg Wang; Kyle D Konze; Jianguo Tao
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 2.  Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Authors:  Jennifer K Lue; Jennifer E Amengual
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 3.  Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Authors:  Bowen Xu; Kyle D Konze; Jian Jin; Gang Greg Wang
Journal:  Exp Hematol       Date:  2015-05-28       Impact factor: 3.084

4.  Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.

Authors:  Rishi G Vaswani; Victor S Gehling; Les A Dakin; Andrew S Cook; Christopher G Nasveschuk; Martin Duplessis; Priyadarshini Iyer; Srividya Balasubramanian; Feng Zhao; Andrew C Good; Robert Campbell; Christina Lee; Nico Cantone; Richard T Cummings; Emmanuel Normant; Steven F Bellon; Brian K Albrecht; Jean-Christophe Harmange; Patrick Trojer; James E Audia; Ying Zhang; Neil Justin; Shuyang Chen; Jon R Wilson; Steven J Gamblin
Journal:  J Med Chem       Date:  2016-10-28       Impact factor: 7.446

Review 5.  Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery.

Authors:  Robert A Copeland
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

Review 6.  Engaging chromatin: PRC2 structure meets function.

Authors:  Paul Chammas; Ivano Mocavini; Luciano Di Croce
Journal:  Br J Cancer       Date:  2019-11-11       Impact factor: 7.640

7.  Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry.

Authors:  Michael D Scholle; Cheng Liu; Jerome Deval; Zachary A Gurard-Levin
Journal:  SLAS Discov       Date:  2021-04-17       Impact factor: 3.341

Review 8.  Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer.

Authors:  Anne Laugesen; Jonas Westergaard Højfeldt; Kristian Helin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

9.  Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.

Authors:  Theresa Baker; Sujata Nerle; Justin Pritchard; Boyang Zhao; Victor M Rivera; Andrew Garner; Francois Gonzalvez
Journal:  Oncotarget       Date:  2015-10-20

10.  Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.

Authors:  Zachary A Gurard-Levin; Cheng Liu; Andreas Jekle; Ruchika Jaisinghani; Suping Ren; Koen Vandyck; Dirk Jochmans; Pieter Leyssen; Johan Neyts; Lawrence M Blatt; Leonid Beigelman; Julian A Symons; Pierre Raboisson; Michael D Scholle; Jerome Deval
Journal:  Antiviral Res       Date:  2020-09-05       Impact factor: 5.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.